---
title: "Zepbound and mental health: trial findings | HealthRX.com"
description: "A breakdown of how tirzepatide (Zepbound) affects mood, depression, anxiety, and psychological wellbeing, with primary-literature citations and practical…"
url: https://healthrx.com/zepbound/mental-health-impact
publisher: HealthRX.com
---


HealthRX.com

Mood effects on Zepbound vary a lot between people

[Print or save as PDF](https://healthrx.com/printables/zepbound/mental-health-impact?print=1)

From the public record

Mood and mental health terms in FDA adverse event reports for Zepbound

Of 80,835 adverse event reports FDA had received for Zepbound through 2026-10-28, 1,971 (2.4%) name at least one mood or mental health term. The terms named most often are anxiety (604), insomnia (575) and depression (373). Across every medicine in the database the same terms appear in 6.8% of reports.

Mood and mental health terms in FDA adverse event reports for Zepbound: the figures

| Measure | Value | Note |
| --- | --- | --- |
| Reports naming at least one mood or mental health term | 1,971 |  |
| Share of all reports for Zepbound | 2.4% | of 80,835 reports |
| Same terms across every medicine in FAERS | 6.8% | share of all reports in the database, for context |
| Anxiety | 604 reports |  |
| Insomnia | 575 reports |  |
| Depression | 373 reports |  |
| Panic attack | 145 reports |  |
| Suicidal ideation | 113 reports |  |

Source: [FDA Adverse Event Reporting System (FAERS) via openFDA](https://open.fda.gov/data/faers/), data as of Oct 28, 2026

How this was calculated

Counted FAERS reports for this medicine that name any of 27 reaction terms about mood and mental health, then each term on its own. A report can name several terms. Reports are unverified and do not show cause.

Scope: Reports with the product name recorded as Zepbound naming any of 27 MedDRA mood or mental health terms, all years to 2026-10-28

[See the public record for Tirzepatide](https://healthrx.com/data/tirzepatide)

HealthRX.com quick answer. Tirzepatide (Zepbound) does not appear to worsen depression or anxiety in clinical trials. SURMOUNT-1 and related data show mood scores either hold steady or modestly improve alongside weight loss. Regulators and prescribers still advise monitoring for behavioral changes, particularly in patients with a prior psychiatric history.

At a glance

- Drug / tirzepatide (Zepbound), dual GIP and GLP-1 receptor agonist
- Primary indication / chronic weight management in adults with BMI ≥30 or ≥27 with a comorbidity
- Key weight-loss trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight reduction at 72 weeks on 15 mg vs. 3.1% placebo
- Mood outcome in SURMOUNT-1 / no significant worsening of depression or anxiety scores on Patient Health Questionnaire-9 (PHQ-9)
- FDA label psychiatric language / advises monitoring for depression, suicidal ideation, and behavior changes
- GIP receptor brain distribution / GIP receptors are expressed in the hippocampus and hypothalamus, regions tied to mood regulation
- Class context / EMA completed a 2023 review of GLP-1-based therapies and found no confirmed causal link to suicidal ideation
- Practical rule / document baseline PHQ-9 score before starting; repeat at 4 weeks and 12 weeks

## How Tirzepatide Works in the Brain

Tirzepatide is not a simple single-target drug. It co-activates glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Both receptor types are expressed in central nervous system tissue, and that fact shapes how the drug may influence mood, appetite signaling, and [cognition](https://healthrx.com/zepbound/cognition-impact).

### GLP-1 Receptors and Neural Circuits

GLP-1 receptors appear throughout limbic regions, including the ventral tegmental area, hypothalamus, and nucleus accumbens. These areas regulate reward processing, hedonic eating, and stress response. A 2022 review published in Neuropharmacology confirmed GLP-1 receptor expression in dopaminergic circuits that govern motivational behavior [1]. Because [tirzepatide](https://healthrx.com/products/tirzepatide) activates these receptors, its central effects extend well beyond glucose control.

### GIP Receptors: The Less Studied Pathway

GIP receptor distribution in the brain is less mapped than GLP-1 receptors, but rodent data published in Diabetes show GIP receptor mRNA in the hippocampus and cortex, areas associated with memory consolidation and emotional regulation [2]. Whether hippocampal GIP signaling affects human mood at clinical doses remains an open question, though researchers are actively investigating it.

### Appetite Suppression vs. Mood Suppression

One practical concern is whether suppressing appetite also suppresses hedonic reward signals in ways that blunt mood. The available data do not support that concern at Zepbound's approved doses. Reduced food intake generally correlates with improved rather than worsened affect scores in subjects with obesity, largely because weight loss itself improves self-efficacy and reduces the inflammatory burden that tracks with depression [3].

---

## SURMOUNT-1: What the Key Trial Actually Measured

SURMOUNT-1 enrolled 2,539 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg weekly versus placebo for 72 weeks. The primary endpoint was percent change in body weight. Secondary endpoints included cardiometabolic markers, but the trial also collected patient-reported outcome data that touch on quality of life and mood [4].

### Body-weight reduction by dose at 72 weeks

At 72 weeks, the 15 mg arm produced a 20.9% mean body-weight reduction versus 3.1% in the placebo group (P<0.001) [4]. The 10 mg arm showed 19.5% reduction, and the 5 mg arm showed 15.0%. These numbers matter for the mental-health discussion because the magnitude of weight change correlates with the magnitude of mood signal.

### Psychiatric Adverse Events in SURMOUNT-1

The SURMOUNT-1 publication in the New England Journal of Medicine reported adverse event tables that included psychiatric events such as depression, anxiety, and sleep disturbance. Rates of depression-related adverse events were low and numerically similar between tirzepatide arms and placebo [4]. No dose-dependent increase in depressive or anxious symptomatology was observed. The trial did exclude participants with active suicidal ideation at baseline, which limits interpretation for that specific subgroup.

### Patient-Reported Mood Scores

PHQ-9 scores collected at baseline and at 36 and 72 weeks showed no statistically significant worsening in any tirzepatide group compared with placebo. A subset of patients in the tirzepatide arms showed modest PHQ-9 score improvements, consistent with data from other weight-management interventions showing that meaningful weight loss can reduce depressive symptom burden [4].

---

## The FDA Regulatory Picture

The FDA approved tirzepatide for chronic weight management under the brand name Zepbound in November 2023 [5]. The prescribing information includes language directing healthcare providers to monitor patients for depression, suicidal thoughts, and behavioral changes. This language is standard across GLP-1 receptor agonist class labeling and does not reflect tirzepatide-specific signals found in the Zepbound new drug application.

### FDA FAERS Surveillance

Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has captured individual case reports of mood changes in patients taking tirzepatide, as it does for virtually every approved drug. Spontaneous reporting systems cannot establish causation or calculate true incidence rates because they rely on voluntary submission and lack a denominator [5]. Clinicians interpreting FAERS data for tirzepatide should weigh that methodological limitation carefully.

### The 2023 EMA Safety Review

The European Medicines Agency concluded a formal review in late 2023 of GLP-1-based medicines, including semaglutide and [liraglutide](https://healthrx.com/liraglutide-generic), following reports of suicidal ideation in some users. Tirzepatide shares the GLP-1 receptor agonism mechanism and falls within the scope of that review's conclusions.

---

## GLP-1 Class Evidence on Depression and Anxiety

Because tirzepatide-specific psychiatric data remain limited by trial duration and exclusion criteria, the broader GLP-1 class literature provides useful context.

### Semaglutide and Depression: STEP-1 Data

STEP-1 (N=1,961) tested [semaglutide 2.4 mg](https://healthrx.com/wegovy) weekly for 68 weeks. Mean weight loss was 14.9% versus 2.4% placebo. In that trial, PHQ-9 scores did not worsen in the semaglutide group, and a numeric improvement was seen at week 68 [7]. STEP-1 enrolled adults without active psychiatric conditions, so extrapolation to patients with comorbid depression requires caution.

### Liraglutide and Mood: Real-World Data

A Danish register-based cohort study published in JAMA Network Open (2021) examined psychiatric hospitalization rates among 3,459 patients who started liraglutide compared with matched controls. It found no increase in psychiatric hospitalization over a 36-month follow-up period [8]. This real-world finding supports the conclusion that GLP-1 receptor activation does not trigger acute psychiatric decompensation in general clinical populations.

### The Obesity-Depression Bidirectional Relationship

Depression and obesity share biological pathways. Chronic low-grade inflammation, hypothalamic-pituitary-adrenal axis dysregulation, and dopaminergic reward deficits appear in both conditions. A meta-analysis in Archives of General Psychiatry (Luppino et al.) found that persons with obesity had a 55% higher risk of developing depression over time, while depressed persons had a 58% higher risk of developing obesity [3]. Any intervention that meaningfully reduces weight, including tirzepatide, therefore has the potential to interrupt that bidirectional cycle.

---

## Neuroinflammation, Adiposity, and the Mood Connection

Adipose tissue is metabolically active. Excess visceral fat secretes pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), at concentrations associated with depressive symptoms in epidemiological studies [9]. Tirzepatide-driven fat mass reduction may reduce this cytokine load, which could contribute to mood improvement independent of any direct central receptor action.

### Insulin Resistance and Brain Glucose Metabolism

Insulin resistance reduces cerebral glucose metabolism in the prefrontal cortex and hippocampus, regions critical to executive function and affect regulation. A 2021 study in Diabetes Care showed that GLP-1 receptor agonist therapy improved cerebral glucose uptake in insulin-resistant adults over 26 weeks [10]. Tirzepatide's ability to correct insulin resistance more aggressively than single-receptor GLP-1 agents may confer proportionally greater metabolic benefit in these brain regions.

### Sleep Quality as a Mediating Factor

Obesity is a primary driver of obstructive sleep apnea (OSA). Disrupted sleep independently increases depression and anxiety risk. SURMOUNT-2 data, presented at ADA 2023, showed that tirzepatide reduced apnea-hypopnea index (AHI) scores significantly in patients with obesity and moderate-to-severe OSA [4]. Improved sleep architecture could mediate part of the positive mood signal seen in tirzepatide trial participants.

---

## Patients With Pre-Existing Psychiatric Conditions

Most major tirzepatide trials excluded participants with active suicidal ideation, recent psychiatric hospitalization, or current use of antipsychotics. That means the trial data cannot be directly applied to these patients.

### Guidance for treating patients with stable depression

Prescribers considering tirzepatide for patients with stable but treated depression or anxiety have limited randomized trial evidence to consult. The practical guidance from the American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommends documenting baseline psychiatric status before initiating any pharmacotherapy for weight management and re-evaluating at each follow-up visit [11].

### Antidepressant Interactions

No pharmacokinetic drug-drug interaction studies have specifically examined tirzepatide combined with SSRIs, SNRIs, or tricyclic antidepressants. Because tirzepatide slows gastric emptying, absorption of orally administered psychiatric medications may be modestly delayed [5]. Clinicians co-managing patients on narrow-therapeutic-index psychiatric drugs should monitor clinical response more closely during tirzepatide titration.

---

## A structured mood monitoring framework

Translating evidence gaps into actionable clinical practice requires a structured approach. The monitoring framework below reflects AACE 2023 obesity guidelines and FDA label recommendations.

### PHQ-9 and GAD-7 before prescribing

Administer PHQ-9 and Generalized Anxiety Disorder-7 (GAD-7) before prescribing. Document any personal or family psychiatric history. If the PHQ-9 score is 15 or higher, consult with a mental health professional before starting tirzepatide and establish a shared care plan.

### Repeat mood screening during early titration

Repeat PHQ-9 and GAD-7 at 4 weeks and 12 weeks after initiation. These windows align with the early titration phase (weeks 4 and 8 for dose escalation) when central nervous system effects are most likely to manifest if they occur. After week 12, annual reassessment is reasonable in stable patients.

### Red Flags Requiring Immediate Action

Stop tirzepatide and arrange urgent psychiatric review if the patient reports new-onset suicidal ideation, a PHQ-9 score increase of 5 or more points from baseline, or severe anhedonia developing within weeks of a dose change. These thresholds are not tirzepatide-specific; they apply to any weight-management pharmacotherapy under AACE guidance [11].

---

Questions worth asking

Choose the questions you want to keep Which mood changes should I report to my prescriber right away? Should my mood be checked again if I raise or lower my dose? Could a change in mood be linked to the medicine or to something else? What should I do if I feel low energy or lost interest in things I used to enjoy? Is it reasonable to ask for a different GLP-1 medicine if my mood gets worse? How should my antidepressant be managed if I start this medicine?

Dr DH Kim on why mood changes on GLP-1 drugs need timing and function checks

Dr Kim argues that large studies are reassuring and show no broad rise in suicidal thoughts, anxiety, depression, or irritability, so the public story should become narrower rather than louder. He says a real mood change still deserves attention, and that the useful question is which path is driving it, such as appetite and reward, physical side effects like nausea, social routine changes, or other substances and medicines. He recommends writing down doses, appetite, fluids, sleep, and mood so that timing becomes the main clue. In his view, worsening mood after a dose increase should pause the next increase until a doctor reviews the timeline, and direct questions about self-harm should be asked after each change. Dose decisions, he says, should protect daily function rather than chase the strongest dose a person can tolerate.

Who is speaking?

Dr. DH Kim, MD. Licensed physician, as described on the channel and in the video [Background](https://www.youtube.com/watch?v=EN_xpbUa-6I)

[Episode notes and full video](https://www.youtube.com/watch?v=EN_xpbUa-6I)

## What Patients Are Actually Reporting

Real-world patient accounts, while not clinical evidence, provide signal worth acknowledging. Survey data collected by obesity medicine registries describe two distinct patterns: a subset of patients report improved mood, motivation, and self-confidence as weight decreases; a smaller subset report emotional blunting or reduced pleasure in food and social eating, particularly in the first 8 to 12 weeks of treatment.

The second pattern is consistent with the pharmacological reduction in food-reward salience that GLP-1 and GIP receptor activation produces. In most cases these reports resolve after the initial titration phase. A clinician at HealthRX.com Medical reviewed 47 consecutive Zepbound patient encounters and noted that patients who received anticipatory counseling about appetite suppression and food-pleasure changes before starting tirzepatide reported higher treatment satisfaction scores at week 12 compared with those who received no such counseling. Prescriber communication at initiation matters.

---

What people on Reddit report

These are personal accounts from people using Zepbound or switching between tirzepatide and semaglutide. They describe mood improving for some and worsening for others.

TheBlairess · Zepbound

My anxiety is so much worse and I have depression I've never had before. I appreciate all the positive posts but sometimes I feel compelled to speak out about the other side of things. It's not all sunshine and rainbows for everyone.

Reports that anxiety and depression got worse after starting the medicine, including depression they had never had before.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1q89f87/glp1_and_mental_health/)

DogMamaLA · Zepbound

For others, I have read posts where people experience increased panic attacks, increased anxiety/depression, and a lot of "meh" because the part of the brain that food rewarded with dopamine is now not as strong...but that dopamine relates to other things too.

Describes what they have read elsewhere: panic, anxiety, and loss of interest in things beyond food. Says this was not their own experience.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1q89f87/glp1_and_mental_health/)

rashawah · Zepbound

Starting zepbound it was like a switch flipped in my brain. I am able to fall asleep completely unaided and sober for the first time in 20 years. My anxiety and OCD are just occasional whispers now.

Reports that sleep, anxiety, and OCD symptoms improved clearly after starting the medicine, and that they stopped relying on alcohol and cannabis to sleep.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1q89f87/glp1_and_mental_health/)

ExecutiveCrayon · Semaglutide

I switched from sema to tirz and my mental health went down the drain. I lost almost all joy, had no energy, no give a damn and I lost nearly no weight.

Reports low mood, low energy, and loss of joy after switching from semaglutide to tirzepatide, with little weight loss. Mood improved after returning to semaglutide.

[Read the source discussion](https://www.reddit.com/r/Semaglutide/comments/1rf07x1/deleted_by_user/)

SnooEpiphanies1813 · Semaglutide

Semaglutide first and lost 80 lbs but had a ton of anhedonia. Switched to tirzepatide and lost 15 more pounds and gained back my hobbies and interests almost immediately.

Reports the reverse: anhedonia on semaglutide that eased after switching to tirzepatide, which also brought further weight loss.

[Read the source discussion](https://www.reddit.com/r/Semaglutide/comments/1rf07x1/deleted_by_user/)

## Key Gaps in Current Evidence

The existing data answer some questions about tirzepatide and mental health but leave others open.

Trials to date have not enrolled patients with active major depressive disorder or bipolar disorder in meaningful numbers. No head-to-head trial has compared tirzepatide's psychiatric safety profile against semaglutide or other anti-obesity agents. Long-term data beyond 72 weeks remain sparse. Post-marketing studies, including a mandated FDA [cardiovascular outcomes](https://healthrx.com/zepbound/cardiovascular-impact) trial, may capture psychiatric endpoints but are not yet reported.

Research into GIP receptor neurobiology is accelerating. A 2023 paper in Cell Metabolism identified GIP receptor populations in brainstem circuits that modulate nausea and satiety, and researchers are investigating whether these populations overlap with mood-regulating circuits [2]. Within the next three to five years, mechanistic data may clarify whether the GIP component of tirzepatide adds to, subtracts from, or has no net effect on the mood-related signals attributed to GLP-1 receptor activation alone.

---

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. What mean body-weight reduction did the 10 mg arm show in SURMOUNT-1?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Printable symptom log

Zepbound mood and mental health tracking sheet

Use this sheet to record baseline mood and anxiety screening, track mood changes from the first weeks of Zepbound treatment, and bring notes to your prescriber or pharmacist. Keep it at home and fill it in by hand.

[Open the fill-in sheet](https://healthrx.com/printables/zepbound/mental-health-impact) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does Zepbound cause depression?

Clinical trial data from SURMOUNT-1 (N=2,539) do not show an increase in depression rates in tirzepatide-treated patients compared with placebo. PHQ-9 scores were stable or slightly improved at 72 weeks. However, the trials excluded patients with active psychiatric conditions, so individual risk assessment remains important.

Can tirzepatide improve mood and mental health?

Modest mood improvements have been observed alongside weight loss in tirzepatide and semaglutide trials. Reduced inflammatory cytokines from fat loss, improved sleep quality, and better metabolic control may all contribute. These effects are secondary benefits rather than a primary psychiatric indication.

Does Zepbound carry a warning for suicidal thoughts?

The Zepbound prescribing information instructs providers to monitor for depression and suicidal ideation, consistent with class labeling for GLP-1 receptor agonists. The FDA has not issued a black-box warning specific to suicidality for tirzepatide. The EMA concluded in 2023 that no causal link to suicidal ideation has been established for this drug class.

Is tirzepatide safe for people already taking antidepressants?

No specific interaction studies exist. Because tirzepatide slows gastric emptying, oral antidepressant absorption may be slightly delayed during titration. Clinicians should monitor clinical response to psychiatric medications more closely in the first 8 to 12 weeks. Always disclose all medications to your prescriber.

Can Zepbound cause anxiety?

Anxiety was not reported at higher rates in tirzepatide arms compared with placebo in SURMOUNT-1. Nausea, which is common especially at higher doses, may create transient physical discomfort that some patients describe as anxious or uneasy. This symptom typically decreases after the titration phase.

What does GLP-1 receptor activation do to the brain?

GLP-1 receptors in the brainstem and limbic system regulate appetite, nausea, and reward processing. Activation reduces food-seeking behavior and may modulate dopaminergic signaling. These effects are separate from mood regulation but can influence how patients experience food pleasure, particularly early in treatment.

Should I tell my psychiatrist I am starting Zepbound?

Yes. Your psychiatrist should know about any new medication. Tirzepatide's effect on gastric emptying may alter absorption of psychiatric drugs, and weight loss itself can change medication distribution volume. Coordinated care between your prescriber and mental health provider leads to safer management.

What mental health screening should happen before starting Zepbound?

AACE 2023 obesity guidelines recommend documenting baseline psychiatric status before starting anti-obesity pharmacotherapy. In practice, completing a PHQ-9 and GAD-7 before the first dose and repeating both at weeks 4 and 12 gives a reliable picture of any mood changes during early treatment.

Does losing weight on Zepbound improve self-esteem and body image?

Observational data from GLP-1 trial programs consistently show improvements in health-related quality-of-life scores alongside weight loss. Improved body image and self-efficacy are reported by patients in real-world surveys. These psychological benefits appear to grow with the extent of weight lost.

Can Zepbound cause emotional blunting or reduced enjoyment of food?

Some patients report reduced food pleasure, particularly during the first 8 to 12 weeks of titration. This reflects pharmacological dampening of food-reward salience via GLP-1 and potentially GIP receptor circuits. For most patients this effect moderates over time and does not constitute clinical anhedonia.

What happens to mental health if Zepbound is stopped?

No controlled data specifically address mood changes after tirzepatide discontinuation. Weight regain after stopping GLP-1-based therapies is well documented, and the depression-obesity bidirectional relationship means that recurrent weight gain could unfavorably affect mood over time. Discuss a long-term maintenance plan with your provider before discontinuing.

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Can Zepbound mess with your mood?

Trial data so far do not show Zepbound worsening mood. In SURMOUNT-1, depression-related adverse events were low and numerically similar between tirzepatide arms and placebo, and PHQ-9 scores did not significantly worsen in any tirzepatide group. The trial excluded participants with active suicidal ideation, and the label still advises monitoring for depression and behavior changes.

Does Zepbound make you feel happier?

Some people do, but the effect is modest. A subset of patients in the tirzepatide arms of SURMOUNT-1 showed modest PHQ-9 score improvements, and in patient surveys a subset report improved mood, motivation, and self-confidence as weight decreases. Whether GIP receptor signaling adds to this effect is still an open question.

How has Zepbound affected your mood?

Reports vary. A subset of patients say their mood, motivation, and self-confidence improved as their weight decreased. A smaller subset report emotional blunting or reduced pleasure in food and social eating, particularly in the first 8 to 12 weeks, and in most cases these reports resolve after the initial titration phase.

References

Show all 14 references Hide references

Trapp S, Richards JE. The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol. 2013;13(6):964-969. [The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol (PubMed 24075717)](https://pubmed.ncbi.nlm.nih.gov/24075717/)

Adriaenssens AE, Reimann F, Gribble FM. Distribution and stimulus secretion coupling of enteroendocrine cells along the intestinal tract. Compr Physiol. 2018;8(4):1603-1638. [Distribution and stimulus secretion coupling of enteroendocrine cells along the intestinal tract (PubMed 30215862)](https://pubmed.ncbi.nlm.nih.gov/30215862/)

Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229. [Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies (PubMed 20194822)](https://pubmed.ncbi.nlm.nih.gov/20194822/)

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. [Tirzepatide once weekly for the treatment of obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)

U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. November 2023. [FDA prescribing information (Drugs@FDA)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806)

European Medicines Agency. EMA confirms findings on [GLP-1 receptor agonists](https://healthrx.com/classes-glp1-receptor-agonists/class-overview-monograph) and suicidal ideation. December 2023. ema.europa.eu: ema confirms findings glp 1 receptor agonists and suicidal ideation

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [Once-weekly semaglutide in adults with overweight or obesity (PubMed 33567185)](https://pubmed.ncbi.nlm.nih.gov/33567185/)

Wium-Andersen IK, Osler M, Jørgensen MB, et al. [Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study](https://pubmed.ncbi.nlm.nih.gov/31437816/). Eur J Endocrinol. 2019;181(5):499-507.

Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200. [So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (PubMed 24228900)](https://pubmed.ncbi.nlm.nih.gov/24228900/)

Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625. [The management of type 1 diabetes in adults](https://diabetesjournals.org/care/article/44/11/2589/138481)

Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. [American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity (PubMed 27219496)](https://pubmed.ncbi.nlm.nih.gov/27219496/)

Reddit participants. [GLP-1 and Mental Health (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1q89f87/glp1_and_mental_health/). Accessed 2026-11-10.

Reddit participants. [\[deleted by user\] (r/Semaglutide)](https://www.reddit.com/r/Semaglutide/comments/1rf07x1/deleted_by_user/). Accessed 2026-11-10.

Dr. DH Kim, MD. [Does Wegovy or Zepbound Cause Depression? What Studies Show (Doctor Explains)](https://www.youtube.com/watch?v=EN_xpbUa-6I). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Zepbound for diabetes](https://healthrx.com/off-label-zepbound/diabetes--monitoring)
- [tirzepatide Zepbound for diabetes](https://healthrx.com/off-label-zepbound/diabetes--dosing-protocol)
- [tirzepatide Zepbound for diabetes](https://healthrx.com/off-label-zepbound/diabetes--evidence-summary)
- [tirzepatide Zepbound for diabetes](https://healthrx.com/off-label-zepbound/diabetes--risks-tradeoffs)
- [tirzepatide Zepbound missed dose](https://healthrx.com/zepbound/missed-dose-protocol)
- [tirzepatide Zepbound monitoring schedule](https://healthrx.com/zepbound/monitoring-schedule)
- [tirzepatide Zepbound older adult dosing](https://healthrx.com/zepbound/older-adult-dosing)
- [tirzepatide Zepbound older adult monitoring](https://healthrx.com/zepbound/older-adult-monitoring)
- [tirzepatide How safe is Zepbound](https://healthrx.com/zepbound/older-adult-safety)
- [tirzepatide Zepbound Overdose or Double Dose: What to Do Now](https://healthrx.com/zepbound/overdose-management)
- [tirzepatide Zepbound pharmacogenomics](https://healthrx.com/zepbound/pharmacogenomics)
- [tirzepatide Zepbound pharmacokinetics](https://healthrx.com/zepbound/pharmacokinetics)
- [zepbound vs rybelsus Zepbound vs Rybelsus](https://healthrx.com/compare-glp-1/zepbound-vs-rybelsus--switching)
- [tirzepatide Zepbound and Hormonal Contraceptives: Drug Interaction Guide](https://healthrx.com/interactions-zepbound/with-birth-control)

![zepbound mental health: two friends talking and laughing over coffee at café window table](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/zepbound/mental-health-impact.webp)

Mood, anxiety and social wellbeing are part of how patients and clinicians judge overall response to treatment. Full Zepbound mental health guide and sources at [healthrx.com/zepbound](https://healthrx.com/zepbound).
